Related Experiment Video
Updated: May 25, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
VEGF-C antisense oligoxydeonucleotide suppression of invasive ability of the A-549 lung carcinoma cell line
Chuanliang Peng1, Qifeng Sun, Yunzhi Fang
1Thoracic Department, Second Hospital of Shandong University, Jinan, China. pechuliang@126.com
Objective:
Vascular endothelial growth factor C (VEGF-C), a member of the VEGF family, has been reported to promote angiogenesis and tumor cell growth. In this study, we analyzed inhibitory action of a VEGF-C antisense oligoxydeonucleotide (ASODN) on a lung carcinoma cell line A-549 and its invasive ability in vitro.
Methods:
Liposomes, liposome-mediated sense oligoxydeonucleotide (SODN) and ASODN were transfected into A-549 cells, with a blank control group. The expression of VEGF-C was examined by western blotting and invasive ability of cells was detected at four levels.
Results:
Lower expression of VEGF-C and lower invasive ability to recombinate basal membranes were apparent in the ASOND group (P<0.01). However, there were no significant differences among the other three groups (P>0.05). In the invasion assay, the number of transmembrane cells was significantly reduced in the ASODN group after 48 hours (58.6±9.2 P<0.01), but there was no variation among control, LIP and SOND groups (132.5±15.6, 129.7±16.1, 118.2±12.5, P>0.05).
Conclusions:
VEGF-C ASODN can downregulate the expression of VEGF-C in cell lines and can obviously inhibit invasive ability in vitro.
Insights
Vascular endothelial growth factor C (VEGF-C) antisense oligodeoxynucleotide (ASODN) effectively reduced VEGF-C expression and inhibited lung cancer cell invasion in vitro. This suggests ASODN as a potential therapeutic strategy for lung carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Vascular endothelial growth factor C (VEGF-C) promotes angiogenesis and tumor growth.
- VEGF-C plays a role in cancer progression, including lung carcinoma.
Purpose of the Study:
- To investigate the inhibitory effect of a VEGF-C antisense oligodeoxynucleotide (ASODN) on the A-549 lung carcinoma cell line.
- To evaluate the impact of ASODN on the invasive capabilities of lung cancer cells in vitro.
Main Methods:
- A-549 cells were transfected with liposomes, sense oligodeoxynucleotide (SODN), and ASODN.
- VEGF-C expression was assessed using Western blotting.
- In vitro cell invasion was measured using a Transwell assay.
Main Results:
- ASODN treatment significantly downregulated VEGF-C expression in A-549 cells.
- A significant reduction in cell invasion was observed in the ASODN group compared to control, liposome (LIP), and SODN groups.
- The number of transmembrane cells was markedly decreased in the ASODN group after 48 hours.
Conclusions:
- VEGF-C ASODN effectively downregulates VEGF-C expression in lung carcinoma cell lines.
- VEGF-C ASODN demonstrates a significant inhibitory effect on the in vitro invasive ability of lung cancer cells.
- ASODN targeting VEGF-C presents a potential therapeutic avenue for lung cancer treatment.
